Want to see AU:IVX full AI Analyst Report?
IVX Stock Chart & Stats
AU$0.08
AU$0.00(0.00%)
At close: 4:00 PM EST
AU$0.08
AU$0.00(0.00%)
Day’s Range― - ―
52-Week RangeAU$0.03 - AU$0.20
Previous CloseN/A
Volume36.17K
Average Volume (3M)97.01K
Market Cap
AU$3.82M
Enterprise ValueAU$4.97M
Total Cash (Recent Filing)AU$137.54K
Total Debt (Recent Filing)AU$627.68K
Price to Earnings (P/E)―
Beta0.32
Next Earnings
Aug 27, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.13
Shares Outstanding109,200,640
10 Day Avg. Volume121,261
30 Day Avg. Volume97,006
Financial Highlights & Ratios
PEG Ratio-0.03
Price to Book (P/B)0.96
Price to Sales (P/S)0.00
P/FCF Ratio-2.67
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Bulls Say, Bears Say
Bulls Say
Conservative Leverage / No DebtHaving no reported debt lowers fixed financial obligations and interest burden, which is durable for a clinical-stage biotech reliant on financing events. This conservatism preserves optionality and reduces bankruptcy risk, extending runway versus leveraged peers.
Focused Clinical-stage Pipeline (IVX-P02)Invion's clear focus on a single photodynamic therapy candidate (IVX-P02) for oncology concentrates R&D resources and clarifies go-to-market strategy. A defined clinical program simplifies partner diligence and can accelerate licensing or collaboration decisions, supporting durable strategic optionality.
Improving Free Cash Flow TrendAn improvement in FY2025 free cash flow versus FY2024 signals progressing cash efficiency or cost control. While still negative, a sustained FCF improvement trend would reduce external funding needs and materially affect long-term viability and financing flexibility.
Bears Say
Revenue Collapse To ZeroRevenue collapsing to zero in FY2025 demonstrates loss of commercial or licensing income, removing internal revenue cushions. For an R&D-focused biotech, lack of revenue forces reliance on dilutive financings or partnerships and raises structural funding uncertainty over the medium term.
Persistent Operating Cash BurnPersistent negative operating cash flow and a ~-2.97M outflow in FY2025 reflect ongoing burn that erodes reserves. Continued cash outflows without a path to operational cash generation increase the need for external capital and heighten dilution and execution risk.
Eroding Equity And AssetsShrinking equity and declining assets indicate eroded balance-sheet resilience and reduced financial flexibility. This deterioration limits ability to self-fund trials, weakens negotiating leverage with partners, and raises the probability of dilutive financing to sustain development programs.
Invion News
IVX FAQ
What was Invion’s price range in the past 12 months?
Invion lowest share price was AU$0.03 and its highest was AU$0.20 in the past 12 months.
What is Invion’s market cap?
Invion’s market cap is AU$3.82M.
When is Invion’s upcoming earnings report date?
Invion’s upcoming earnings report date is Aug 27, 2026 which is in 37 days.
How were Invion’s earnings last quarter?
Invion released its earnings results on Feb 26, 2026. The company reported -AU$0.042 earnings per share for the quarter, missing the consensus estimate of N/A by -AU$0.042.
Is Invion overvalued?
According to Wall Street analysts Invion’s price is currently Overvalued.
Does Invion pay dividends?
Invion does not currently pay dividends.
What is Invion’s EPS estimate?
Invion’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Invion have?
Invion has 109,200,640 shares outstanding.
What happened to Invion’s price movement after its last earnings report?
Invion reported an EPS of -AU$0.042 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -1.235%.
Which hedge fund is a major shareholder of Invion?
Currently, no hedge funds are holding shares in AU:IVX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Invion Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Technicals
SMA
Negative
20 days / 200 days
Momentum
-28.00%
12-Months-Change
Fundamentals
Return on Equity
―
Trailing 12-Months
Asset Growth
-37.10%
Trailing 12-Months
Company Description
Invion
Invion Limited, an Australian clinical-stage life sciences enterprise, is actively engaged in the research and development of photodynamic therapy (PDT) to address various cancer types. Its flagship offering, IVX-PDT, is a photosensitizer agent being developed to combat skin cancers alongside a range of solid tumors, including those affecting the lungs, prostate, ovaries, and mesothelioma. The company has forged a research and development alliance with the Hudson Institute of Medical Research, jointly pursuing R&D initiatives for its Photosoft technology across a broad spectrum of cancer treatments. Moreover, a dedicated research agreement with the Peter MacCallum Cancer Centre facilitates pre-clinical and in-vitro investigations into Invion's IVX-PDT for ano-genital cancers, such as penile and anal cancers. The firm was established in 2000 and is headquartered in Melbourne, Australia.
Technical Analysis
Percheron Therapeutics
―
Argent Biopharma
―
Medical Developments International Limited
―
Althea Group Holdings Ltd.
―
IDT Australia Limited
―